# A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

> **NCT02757768** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 715 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia
- Overactive Bladder

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Placebo
- **DRUG:** Tamsulosin Hydrochloride

## Key facts

- **NCT ID:** NCT02757768
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-13
- **Primary completion:** 2018-08-14
- **Final completion:** 2018-09-11
- **Target enrollment:** 715 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02757768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02757768, "A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02757768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*